Leggett action continues
Tuesday, 16 September, 2008
Legal action against former Agenix CEO Neil Leggett is set to re-commence before the Supreme Court of Victoria on September 26.
Agenix [ASX: AGX] is taking action against Leggett, a former CEO, CFO and company secretary, alleging financial irregularities involving $3.865 million.
Agenix alleges that improper transactions occurred between it and a trustee company of Leggett’s family trust.
A stay of proceedings was ordered on September 12 as the trustee company has been placed into a creditor’s voluntary liquidation.
Leggett was with the company between 2003 and May 2008.
Agenix has been hit with further problems recently, with an intended acquisition in China stalling and two directors and the company chairman resigning in August.
It recently received a patent for its ThromboView technology in New Zealand. ThromboView is a humanised D-dimer antibody diagnostic with a range of imaging and therapeutic applications.
It is currently in Phase II trials in Canada and the US for the detection of pulmonary embolism.
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
